Skip to main content

Table 2 Clinicopathologic characteristics of PDAC patients UICC stage II with different adjuvant chemotherapy response

From: MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II

 

Total

PDAC II w/o CTX

PDAC II w CTX

P

P

Good response

Bad response

(n = 91)

I (n = 27)

II (n = 25)

III (n = 39)

 

II vs. III

Age (years)

      

 ≤65

41

10

12

19

0.5092

1

 median (range)

 

63 (54–65)

56 (41–64)

53 (31–65)

  

 >65

50

17

13

20

  

 median (range)

 

72 (66–84)

73 (66–84)

71 (67–79)

  

Gender

      

 Female

41

14

11

16

0.6801

1

 Male

50

13

14

23

  

UICC stage

      

 IIa

29

7

9

13

0.6469

1

 IIb

62

20

16

23

  

Grading

      

 G1

5

0

3

2

0.0231

0.5008

 G2

50

10

16

24

  

 G3

36

17

6

13

  

Perineural invasion

      

 Pn0

32

10

10

12

0.7305

0.5904

 Pn1

59

17

15

27

  

Vene invasion

      

 V0

74

23

22

29

0.3256

0.2204

 V1

17

4

3

10

  

Lymphatic invasion

      

 L0

50

17

15

18

0.3367

0.3149

 L1

41

10

10

21

  

Resection margin

      

 R0

67

20

21

26

0.3071

0.1553

 R1

24

7

4

13

  

Type of surgery

      

 Pancreatic head resection

75

26

17

32

0.0276

0.2347

  Traverso-Longmire

66

22

15

29

  

  Whipple-Kausch

9

4

2

3

  

 Pancreatic left resection

16

1

8

7

  

Adjuvant gemcitabine

      

 Yes

64

0

25

39

0.0000

1

 No

27

27

0

0

  

Tumor recurrence

      

 ≤18 months

63

24

0

39

0.0000

0.0001

 >18 months

5

2

3

0

  

Tumor related death

      

 ≤18 months

39

20

0

19

0.0234

0.0856

 >18 months

22

6

3

13

  
  1. p < 0.05 indicates significance